13F HOLDINGS REPORT
TAKEDA PHARMACEUTICAL CO LTD
Quarter ended Q4 2024 · Filed February 13, 2025 · Accession 0001395064-25-000024
Total Value
$327.5M
Positions
16
Other Managers
1
Confidential Omitted
No
Holdings (16)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | HilleVax, Inc. | 43157M102 | 6,724,000 | $107.9M | 32.95% |
| 2 | Denali Therapeutics Inc. | DNLI | 4,214,559 | $86.9M | 26.55% |
| 3 | Phathom Pharmaceuticals, Inc. | PHAT | 7,459,286 | $77.4M | 23.62% |
| 4 | Ovid Therapeutics Inc. | OVID | 5,750,000 | $18.5M | 5.65% |
| 5 | Shattuck Labs, Inc. | STTK | 2,090,858 | $14.9M | 4.55% |
| 6 | Wave Life Sciences Ltd. | WVE | 1,096,892 | $6.3M | 1.93% |
| 7 | Ovid Therapeutics Inc. | OVID | 1,781,996 | $5.7M | 1.75% |
| 8 | American Well Corp | AMWL | 1,554,669 | $2.3M | 0.71% |
| 9 | Turnstone Biologics Corp. | 90042W100 | 895,824 | $2.3M | 0.70% |
| 10 | Equillium, Inc. | EQ | 1,824,977 | $1.3M | 0.40% |
| 11 | Wave Life Sciences Ltd. | WVE | 250,000 | $1.3M | 0.39% |
| 12 | Rani Therapeutics Holdings, Inc. | RANI | 338,679 | $1.1M | 0.34% |
| 13 | Xilio Therapeutics, Inc. | XLO | 1,475,121 | $811,316 | 0.25% |
| 14 | Akili, Inc. | 00974B107 | 738,819 | $359,805 | 0.11% |
| 15 | Aerovate Therapeutics, Inc. | 008064107 | 13,580 | $307,315 | 0.09% |
| 16 | STANDARD BIOTOOLS INC. | LAB | 16,515 | $36,498 | 0.01% |